Pharma Stocks

Bristol Myers Squibb: Value Stock Analysis for Dividend Investors in 2026 – News and Statistics

Apr 14, 2026

The pharmaceutical industry is often viewed as a high-growth yet risky sector, but some companies within it may align with value investing principles. According to a report from Yahoo Finance, these firms typically appear undervalued, offer high dividend yields, and produce steady revenue streams.

Bristol Myers Squibb as a Value Candidate

Bristol Myers Squibb currently presents several metrics that appeal to value investors. Its forward price-to-earnings ratio is approximately 9.5, a figure lower than that of some industry peers. The company’s dividend yield is 4.2%, and it has raised its dividend for 17 consecutive years while maintaining dividend payments for 94 years.

Revenue was reported at $48.3 billion in 2024 and $48.2 billion the following year. Projections for the current year anticipate revenue between $46 billion and $47.5 billion, indicating a degree of consistency despite a slight expected decline.

Market Concerns Underpinning Valuation

This valuation opportunity exists alongside several market concerns. Revenue from the company’s legacy portfolio decreased significantly from 2024 to 2025. A key drug within that portfolio, which generated substantial sales last year, is approaching a patent expiration.

Additionally, some investors are focused on the company’s considerable debt level and a recent agreement for a major acquisition. These factors collectively contribute to a forward price-to-earnings ratio that implies subdued future expectations relative to other pharmaceutical stocks.

Interactive table based on the Store Companies dataset for this report.


# Company Headquarters Focus Scale Note
1 Pfizer Inc. New York, New York Broad pharmaceuticals incl. penicillins Global giant Original penicillin developer, major antibiotic portfolio
2 Merck & Co. Inc. Rahway, New Jersey Broad pharmaceuticals incl. antibiotics Global giant Key player in anti-infectives research and production
3 Bristol Myers Squibb New York, New York Broad pharmaceuticals incl. anti-infectives Global giant Significant legacy and portfolio in antibiotics
4 Eli Lilly and Company Indianapolis, Indiana Broad pharmaceuticals incl. anti-infectives Global giant Historically significant in antibiotic production
5 AbbVie Inc. North Chicago, Illinois Broad pharmaceuticals, legacy antibiotics Global giant Portfolio includes legacy antibiotic products
6 Johnson & Johnson New Brunswick, New Jersey Healthcare conglomerate, anti-infectives Global giant Janssen division involved in anti-infective R&D
7 Amgen Inc. Thousand Oaks, California Biotech, some anti-infective involvement Global large Biotech with capabilities in complex therapeutics
8 Gilead Sciences Foster City, California Antivirals, some antibacterial research Global large Major anti-infective company, focus on antivirals
9 Viatris Inc. Canonsburg, Pennsylvania Generics and biosimilars, antibiotics Global large Large portfolio includes generic antibiotics
10 Teva Pharmaceuticals USA Parsippany, New Jersey Generics, including penicillin derivatives Global large Major generic manufacturer of various antibiotics
11 Sandoz Inc. (US HQ) Princeton, New Jersey Generics, including penicillins Global large Novartis generics division, US HQ, major antibiotic producer
12 Hikma Pharmaceuticals PLC (US Op) Berkeley Heights, New Jersey Generics and injectables, antibiotics Global medium US operations significant for injectable antibiotics
13 Aurobindo Pharma USA East Windsor, New Jersey Generics, including oral penicillins Global medium US subsidiary of Indian firm, manufactures in US
14 Lupin Pharmaceuticals Inc. Baltimore, Maryland Generics, anti-infectives portfolio Global medium US arm of Lupin, produces antibiotic generics
15 Astellas Pharma US Inc. Northbrook, Illinois Specialty pharma, anti-infectives Global medium US subsidiary of Japanese firm, markets antibiotics
16 Melinta Therapeutics Morristown, New Jersey Anti-infectives, novel antibiotics US focused Pure-play antibiotic company, commercializes novel therapies
17 Paratek Pharmaceuticals Boston, Massachusetts Novel tetracycline-derived antibiotics US focused Specialized in modern antibiotic development
18 Nabriva Therapeutics (US) King of Prussia, Pennsylvania Novel antibiotics for resistant infections US focused Developed pleuromutilin class antibiotics
19 Cumberland Pharmaceuticals Nashville, Tennessee Hospital drugs, including anti-infectives US small-medium Portfolio includes antibiotic products
20 Xellia Pharmaceuticals Buffalo Grove, Illinois Anti-infective APIs and finished products Global medium Specializes in anti-infectives, US HQ for Americas
21 AcelRx Pharmaceuticals Hayward, California Acute care, some anti-infective adjacents US small Primarily analgesia, in hospital infection setting
22 Cipla USA Inc. Miami, Florida Generics, respiratory and anti-infectives Global medium US subsidiary, markets antibiotic products
23 Sun Pharmaceutical Industries Inc. Cranbury, New Jersey Generics, broad portfolio incl. antibiotics Global large US operations market generic antibiotics
24 Wockhardt USA LLC Parsippany, New Jersey Generics, complex antibiotics Global medium US arm, known for manufacturing sterile antibiotics
25 Fresenius Kabi USA Lake Zurich, Illinois Generics and injectables, antibiotics Global large Major supplier of injectable hospital antibiotics
26 Baxter International Inc. Deerfield, Illinois Hospital products, injectable antibiotics Global large Manufactures and markets injectable anti-infectives
27 Hospira (Pfizer) Lake Forest, Illinois Injectables, including antibiotics Global large Now part of Pfizer, major injectable antibiotic source
28 Apotex Corp. (US HQ) Weston, Florida Generics, including antibiotic products Global medium US headquarters for Canadian generics firm
29 Amneal Pharmaceuticals Bridgewater, New Jersey Generics and biosimilars, antibiotics Global medium Generic portfolio includes anti-infectives
30 Zydus Pharmaceuticals USA Inc. Pennington, New Jersey Generics, portfolio includes antibiotics Global medium US subsidiary markets generic antibiotic products

This report provides a comprehensive view of the penicillins or streptomycins medicaments industry in the United States, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.

Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the penicillins or streptomycins medicaments landscape in the United States.

Quick navigation

Key findings

  • Domestic demand is shaped by both household and industrial usage, with trade flows linking local supply to imports and exports.
  • Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.
  • Supply depends on input availability and production efficiency, creating a distinct national cost curve.
  • Market concentration varies by segment, creating different competitive landscapes and entry barriers.
  • The 2035 outlook highlights where capacity investment and demand growth are most aligned within the country.

Report scope

The report combines market sizing with trade intelligence and price analytics for the United States. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.

  • Market size and growth in value and volume terms
  • Consumption structure by end-use segments
  • Production capacity, output, and cost dynamics
  • Trade flows, exporters, importers, and balances
  • Price benchmarks, unit values, and margin signals
  • Competitive context and market entry conditions

Product coverage

  • Prodcom 21201160 – Medicaments of penicillins, streptomycins or derivatives thereof, in doses or p.r.s.

Country coverage

Country profile and benchmarks

This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for the United States. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.

Methodology

The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.

  • International trade data (exports, imports, and mirror statistics)
  • National production and consumption statistics
  • Company-level information from financial filings and public releases
  • Price series and unit value benchmarks
  • Analyst review, outlier checks, and time-series validation

All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.

Forecasts to 2035

The forecast horizon extends to 2035 and is based on a structured model that links penicillins or streptomycins medicaments demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in the United States.

  • Historical baseline: 2012-2025
  • Forecast horizon: 2026-2035
  • Scenario-based sensitivity to income growth, substitution, and regulation
  • Capacity and investment outlook for major producing companies

Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.

Price analysis and trade dynamics

Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.

  • Price benchmarks by country and sub-region
  • Export and import unit value trends
  • Seasonality and calendar effects in trade flows
  • Price outlook to 2035 under baseline assumptions

Profiles of market participants

Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.

  • Business focus and production capabilities
  • Geographic reach and distribution networks
  • Cost structure and pricing strategy indicators
  • Compliance, certification, and sustainability context

How to use this report

  • Quantify domestic demand and identify the most attractive segments
  • Evaluate export opportunities and prioritize target destinations
  • Track price dynamics and protect margins
  • Benchmark performance against leading competitors
  • Build evidence-based forecasts for investment decisions

This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of penicillins or streptomycins medicaments dynamics in the United States.

FAQ

What is included in the penicillins or streptomycins medicaments market in the United States?

The market size aggregates consumption and trade data, presented in both value and volume terms.

How are the forecasts to 2035 built?

The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.

Does the report cover prices and margins?

Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.

Which benchmarks are included?

The report benchmarks market size, trade balance, prices, and per-capita indicators for the United States.

Can this report support market entry decisions?

Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.

  1. 1. INTRODUCTION

    Report Scope and Analytical Framing

    1. Report Description
    2. Research Methodology and the Analytical Framework
    3. Data-Driven Decisions for Your Business
    4. Glossary and Product-Specific Terms
  2. 2. EXECUTIVE SUMMARY

    Concise View of Market Direction

    1. Key Findings
    2. Market Trends
    3. Strategic Implications
    4. Key Risks and Watchpoints
  3. 3. DOMESTIC MARKET SIZE AND DEVELOPMENT PATH

    Market Size, Growth and Scenario Framing

    1. Market Size: Historical Data (2012-2025) and Forecast (2026-2035)
    2. Growth Outlook and Market Development Path to 2035
    3. Growth Driver Decomposition
    4. Scenario Framework and Sensitivities
  4. 4. CATEGORY SCOPE, DEFINITIONS AND BOUNDARIES

    Commercial and Technical Scope

    1. What Is Included and How the Market Is Defined
    2. Market Inclusion Criteria
    3. Product / Category Definition
    4. Exclusions and Boundaries
    5. Distinction From Adjacent Products and Substitute Categories
  5. 5. CATEGORY STRUCTURE, SEGMENTATION AND PRODUCT MATRIX

    How the Market Splits Into Decision-Relevant Buckets

    1. By Product Type / Configuration
    2. By Application / End Use
    3. By Customer / Buyer Type
    4. By Channel / Business Model / Technology Platform
    5. Segment Attractiveness Matrix
    6. Product Matrix and Segment Growth Logic
  6. 6. DOMESTIC DEMAND, CUSTOMER AND BUYER ARCHITECTURE

    Where Demand Comes From and How It Behaves

    1. Consumption / Demand: Historical Data (2012-2025) and Forecast (2026-2035)
    2. Demand by End-Use and Buyer Group
    3. Demand by Customer / Consumer Segment
    4. Purchase Criteria, Switching Logic and Adoption Barriers
    5. Replacement, Replenishment and Installed-Base Dynamics
    6. Future Demand Outlook
  7. 7. DOMESTIC PRODUCTION, SUPPLY AND VALUE CHAIN

    Supply Footprint and Value Capture

    1. Production in the Country
    2. Domestic Manufacturing Footprint
    3. Capacity, Bottlenecks and Supply Risks
    4. Value Chain Logic and Margin Pools
    5. Distribution and Route-to-Market Structure
  8. 8. IMPORTS, EXPORTS AND SOURCING STRUCTURE

    Trade Flows and External Dependence

    1. Exports
    2. Imports
    3. Trade Balance
    4. Import Dependence
    5. Sourcing Risks and Resilience
  9. 9. PRICING, PROMOTION AND COMMERCIAL MODEL

    Price Formation and Revenue Logic

    1. Domestic Price Levels and Corridors
    2. Pricing by Segment / Specification / Channel
    3. Cost Drivers and Margin Logic
    4. Promotion, Discounting and Procurement Patterns
    5. Revenue Quality and Commercial Levers
  10. 10. COMPETITIVE LANDSCAPE AND PORTFOLIO POWER

    Who Wins and Why

    1. Market Structure and Concentration
    2. Competitive Archetypes
    3. Segment-by-Segment Competitive Intensity
    4. Portfolio Breadth and Product Positioning
    5. Capability Matrix
    6. Strategic Moves, Partnerships and Expansion Signals
  11. 11. DOMESTIC MARKET STRUCTURE AND CHANNEL LOGIC

    How the Domestic Market Works

    1. Core Demand Centers
    2. Local Production and Distribution Roles
    3. Channel Structure
    4. Buyer and Procurement Architecture
    5. Regional Imbalances Within the Country
  12. 12. GROWTH PLAYBOOK AND MARKET ENTRY

    Commercial Entry and Scaling Priorities

    1. Where to Play
    2. How to Win
    3. Distributor / Partner / Direct Entry Options
    4. Capability Thresholds
    5. Entry Risks and Mitigation
  13. 13. WHERE TO PLAY NEXT: MOST ATTRACTIVE GROWTH OPPORTUNITIES

    Where the Best Expansion Logic Sits

    1. Most Attractive Product Niches
    2. Most Attractive Customer Segments
    3. White Spaces and Unsaturated Opportunities
    4. High-Margin and Underpenetrated Pockets
    5. Most Promising Product Adjacencies
  14. 14. PROFILES OF MAJOR COMPANIES

    Leading Players and Strategic Archetypes

    1. Leading Manufacturers and Suppliers
    2. Production Footprint and Capacities
    3. Product Portfolio and Segment Focus
    4. Pricing Positioning and Indicative Price Logic
    5. Channel / Distribution Strength
    6. Strategic Archetypes
  15. 15. METHODOLOGY, SOURCES AND DISCLAIMER

    How the Report Was Built

    1. Modeling Logic
    2. Source Register
    3. Publications, Regulatory and Industry References
    4. Analytical Notes
    5. Disclaimer

Loading News content from Store report…

Pfizer Inc.

Original penicillin developer, major antibiotic portfolio

Merck & Co. Inc.

Key player in anti-infectives research and production

Bristol Myers Squibb

Significant legacy and portfolio in antibiotics

Eli Lilly and Company

Historically significant in antibiotic production

AbbVie Inc.

Portfolio includes legacy antibiotic products

Johnson & Johnson

Janssen division involved in anti-infective R&D

Amgen Inc.

Biotech with capabilities in complex therapeutics

Gilead Sciences

Major anti-infective company, focus on antivirals

Viatris Inc.

Large portfolio includes generic antibiotics

Teva Pharmaceuticals USA

Major generic manufacturer of various antibiotics

Sandoz Inc. (US HQ)

Novartis generics division, US HQ, major antibiotic producer

Hikma Pharmaceuticals PLC (US Op)

US operations significant for injectable antibiotics

Aurobindo Pharma USA

US subsidiary of Indian firm, manufactures in US

Lupin Pharmaceuticals Inc.

US arm of Lupin, produces antibiotic generics

Astellas Pharma US Inc.

US subsidiary of Japanese firm, markets antibiotics

Melinta Therapeutics

Pure-play antibiotic company, commercializes novel therapies

Paratek Pharmaceuticals

Specialized in modern antibiotic development

Nabriva Therapeutics (US)

Developed pleuromutilin class antibiotics

Cumberland Pharmaceuticals

Portfolio includes antibiotic products

Xellia Pharmaceuticals

Specializes in anti-infectives, US HQ for Americas

AcelRx Pharmaceuticals

Primarily analgesia, in hospital infection setting

Cipla USA Inc.

US subsidiary, markets antibiotic products

Sun Pharmaceutical Industries Inc.

US operations market generic antibiotics

Wockhardt USA LLC

US arm, known for manufacturing sterile antibiotics

Fresenius Kabi USA

Major supplier of injectable hospital antibiotics

Baxter International Inc.

Manufactures and markets injectable anti-infectives

Hospira (Pfizer)

Now part of Pfizer, major injectable antibiotic source

Apotex Corp. (US HQ)

US headquarters for Canadian generics firm

Amneal Pharmaceuticals

Generic portfolio includes anti-infectives

Zydus Pharmaceuticals USA Inc.

US subsidiary markets generic antibiotic products

Loading Reviews content from Store report…

Loading Dashboard content from Store report…

Loading Macro Indicators content from Store report…

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button